Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Molecular Cancer Therapeutics
Nicolas Floc'hDarren A E Cross

Abstract

EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non-small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally unresponsive to first- and second-generation EGFR inhibitors, and current standard of care for NSCLC patients with EGFR Ex20Ins is conventional cytotoxic chemotherapy. Therefore, the development of an EGFR TKI that can more effectively target NSCLC with EGFR Ex20Ins mutations represents a major advance for this patient subset. Osimertinib is a third-generation EGFR TKI approved for the treatment of advanced NSCLC harboring EGFR T790M; however, the activity of osimertinib in EGFR Ex20Ins NSCLC has yet to be fully assessed. Using CRISPR-Cas 9 engineered cell lines carrying the most prevalent Ex20Ins mutations, namely Ex20Ins D770_N771InsSVD (22%) or Ex20Ins V769_D770InsASV (17%), and a series of patient-derived xenografts, we have characterized osimertinib and AZ5104 (a circulating metabolite of osimertinib) activities against NSCLC harboring Ex20Ins. We report that osimertinib and AZ5104 inhibit signaling pathways and cellular growth in Ex20Ins mutant cell lines in vitro and demonstrate sustained tumor growth inhibition of EGFR-mutant tumor xenograft harboring the most prev...Continue Reading

References

Feb 24, 2007·Nature Reviews. Cancer·Sreenath V SharmaDaniel A Haber
Jan 19, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Geoffrey R OxnardPasi A Jänne
May 23, 2014·JAMA : the Journal of the American Medical Association·Mark G KrisPaul A Bunn
Apr 30, 2015·The New England Journal of Medicine·Pasi A JänneMalcolm Ranson
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Jan 19, 2019·Future Oncology·Jennifer W Carlisle, Suresh S Ramalingam
Jan 23, 2019·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Ali SaberHidde J Haisma
Jun 26, 2020·Expert Review of Anticancer Therapy·Kamya SankarAngel Qin
Oct 26, 2018·Therapeutic Advances in Respiratory Disease·Biagio RicciutiRita Chiari
May 3, 2019·Proceedings of the National Academy of Sciences of the United States of America·Shinnosuke IkemuraKenzo Soejima
Jun 25, 2020·EJNMMI Radiopharmacy and Chemistry·Louis AllottEric O Aboagye
Mar 12, 2019·Signal Transduction and Targeted Therapy·Simon Vyse, Paul H Huang
Aug 30, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Susan E JorgeDaniel B Costa
Sep 29, 2019·Seminars in Cancer Biology·Peter T HarrisonPaul H Huang
Nov 6, 2020·Cancer Research·Giovanni RossiCarlo Genova
Jan 12, 2020·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·B van VeggelA J de Langen
Sep 27, 2020·Cancer Treatment Reviews·Jordi RemonBenjamin Besse
Jan 14, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·James Chih-Hsin YangEdward S Kim
Jul 22, 2020·Chemical Reviews·Richard A WardPaul D Smith
Jul 29, 2021·ELife·Ioannis GaldadasFrancesco Luigi Gervasio
Aug 29, 2021·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·D GengX Li
Dec 17, 2021·Expert Review of Anticancer Therapy·Simon Vyse, Paul H Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.